Overview
Survodutide (BI 456906) is a dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim in collaboration with Zealand Pharma. The compound represents a distinct approach to metabolic disease by combining the appetite-suppressing effects of GLP-1 agonism with the energy expenditure and hepatic fat-clearing effects of glucagon receptor activation.
Phase 2 trial results demonstrated impressive weight loss of up to 18.7% at 46 weeks and, critically, showed remarkable efficacy in reducing liver fat—making it one of the most promising candidates for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Survodutide reduced liver fat by up to 86% in some participants, with 83% achieving resolution of steatosis.
The dual agonist approach differentiates survodutide from pure GLP-1 agonists like semaglutide by adding the metabolic benefits of glucagon: increased hepatic fatty acid oxidation, enhanced energy expenditure, and improved lipid profiles. Unlike retatrutide (which adds GIP agonism as well), survodutide focuses specifically on the glucagon/GLP-1 combination.
Phase 3 trials are underway for both obesity and MASH indications, with survodutide positioned as a potential best-in-class therapy for patients with overlapping obesity and liver disease.
Quick facts
- Mechanism
- Dual glucagon/GLP-1 agonist for weight loss and liver fat reduction
- Primary use
- Obesity, MASH/NASH, & Metabolic Disease
- Evidence
- moderate
- FDA
- Not approved
- Route
- Subcutaneous injection (once weekly)
- Typical results
- Up to 18.7% body weight loss at 46 weeks; significant liver fat reduction
Chemical information
Survodutide is a peptide with a molecular mass of approximately 4,231.6 g/mol (C₁₉₂H₂₈₉N₄₇O₆₁). It is based on a modified oxyntomodulin sequence engineered for balanced GLP-1 and glucagon receptor activation. A fatty acid modification enables albumin binding for extended half-life and once-weekly dosing.
How Survodutide works
Survodutide simultaneously activates GLP-1 and glucagon receptors with a carefully balanced ratio of approximately 5:1 (GLP-1:glucagon activity). This ratio is optimized to maximize the metabolic benefits of glucagon agonism while ensuring GLP-1-mediated insulin secretion prevents hyperglycemia.
GLP-1 receptor activation suppresses appetite through central nervous system satiety pathways, delays gastric emptying, and enhances glucose-dependent insulin secretion. These effects are well-established from approved GLP-1 receptor agonists and provide the foundation for survodutide's weight loss efficacy.
Glucagon receptor activation contributes additional metabolic effects not achievable with GLP-1 alone: increased hepatic fatty acid beta-oxidation (clearing liver fat), enhanced thermogenesis and energy expenditure, reduced circulating amino acid levels, and stimulation of FGF-21 secretion. FGF-21 is a metabolic hormone with its own weight-reducing and insulin-sensitizing properties.
The hepatic effects of glucagon agonism make survodutide particularly compelling for MASH/NASH: by driving fatty acid oxidation in the liver, glucagon directly addresses the intrahepatic triglyceride accumulation that drives steatohepatitis. This mechanism is complementary to, and potentially more direct than, the indirect liver fat reduction seen with weight loss from GLP-1 agonists alone.
- GLP-1 pathway: Central appetite suppression, gastric emptying delay, glucose-dependent insulinotropic action
- Glucagon pathway: Hepatic fat oxidation, energy expenditure increase, FGF-21 stimulation
- Liver-directed effect: Direct clearance of intrahepatic triglycerides via glucagon-driven beta-oxidation
- Thermogenesis: Glucagon activates brown adipose tissue and increases resting metabolic rate
- Lipid improvement: Reduces circulating triglycerides, VLDL, and improves overall lipid panel
- Balanced glucose control: GLP-1 insulin secretion offsets glucagon hyperglycemic potential
Pharmacokinetics
Data from Phase 1 and Phase 2 clinical trials.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (SC) | ~75% (estimated) | Good subcutaneous absorption |
| Half-life | ~5–6 days | Supports once-weekly dosing |
| Tmax | 12–48 hours | Relatively rapid absorption |
| Protein binding | >99% (albumin) | Fatty acid acylation extends duration |
| Steady state | 3–4 weeks | Full pharmacodynamic effects after titration |
| Metabolism | Proteolytic degradation | No significant CYP interactions |
Dosing & administration
In Phase 2 obesity trials, survodutide was titrated from 0.3 mg weekly to maximum doses of 4.8 mg or 6.0 mg over 20 weeks. The escalation schedule was 0.3 → 0.6 → 1.2 → 1.8 → 2.4 → 3.6 → 4.8 mg (with optional increase to 6.0 mg). This gradual approach minimized GI adverse effects.
For the MASH indication, similar dose titration was used with the 4.8 mg dose showing the best balance of liver fat reduction and tolerability.
Survodutide is not yet commercially available. Dosing will be finalized based on Phase 3 trial outcomes.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Survodutide's safety profile in Phase 2 trials was consistent with the incretin drug class. GI side effects were dose-dependent and generally manageable with proper titration. Hepatic safety markers improved rather than worsened, supporting its liver-protective properties.
Common
- • Nausea (dose-dependent, 20–40%)
- • Vomiting (10–20%)
- • Diarrhea
- • Decreased appetite
- • Injection site reactions
- • Dyspepsia
Serious / potential risks
- • Severe GI events (managed with dose titration)
- • Increased heart rate (modest increase observed)
- • Pancreatitis monitoring (incretin class)
- • Gallbladder events with rapid weight loss
- • Potential hepatic effects (monitoring included in trials)
Drug interactions
Based on pharmacological mechanism and incretin class experience.
| Medication | Interaction | Recommendation |
|---|---|---|
| Insulin | Additive glucose-lowering; hypoglycemia risk | Reduce insulin dose when initiating; monitor frequently |
| Sulfonylureas | Increased hypoglycemia risk | Dose reduction recommended |
| Oral medications | Gastric emptying delay affects absorption | Take critical medications before survodutide dosing |
| Anticoagulants | Absorption timing may be altered | Monitor INR during dose escalation |
| Hepatically metabolized drugs | Changes in liver fat metabolism could theoretically affect CYP activity | Monitor drug levels for narrow therapeutic index medications |
Storage & handling
Pre-filled Pen (Expected)
- • Refrigerate at 2–8°C before first use
- • Room temperature stability expected for in-use period
- • Protect from light and freezing
- • Single-use disposable pen anticipated
Clinical Trial Formulation
- • Stored per clinical trial protocols
- • Strict cold chain maintenance
- • Research use only
- • Monitored supply chain
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Clinical trials | Not commercially available | Phase 3 trials ongoing |
| Projected pricing | $800–$1,300/month (estimated) | Expected to be competitive with GLP-1 agonist pricing |
| MASH indication | Potentially premium pricing | First-in-class for MASH could command higher price |
The bottom line
Survodutide is a metabolic compound with research interest in weight loss, glp-1/glucagon, nash, liver health. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying metabolic regulation and energy homeostasis
- • Individuals interested in weight loss under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] le Roux CW, Steen O, Lucas KJ, et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol (2024). doi: 10.1016/S2213-8587(23)00356-X PMID: 38142707
- [2] Sanyal AJ, Bedossa P, Engel SS, et al.. Survodutide in patients with MASH and fibrosis. N Engl J Med (2024).
- [3] Day JW, Ottaway N, Patterson JT, et al.. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol (2009). doi: 10.1038/nchembio.209 PMID: 19915529
- [4] Ambery P, Parker VE, Sherrington L, et al.. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet (2018). doi: 10.1016/S0140-6736(18)30726-8 PMID: 29893216